Alkermes (ALKS) Cash from Investing Activities (2010 - 2026)

Alkermes' (ALKS) quarterly Cash from Investing Activities came in at -$2.1 billion in Q1 2026, down 22919.16% year-on-year from N/an in Q1 2025, and down 744.34% on a QoQ basis from $322.3 million in Q4 2025.

Alkermes (ALKS) Cash from Investing Activities (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has 17 years of Cash from Investing Activities data on file, last reported at -$2.1 billion in Q1 2026.

  • On a quarterly basis, Cash from Investing Activities fell 22919.16% year-over-year to -$2.1 billion in Q1 2026; TTM through Mar 2026 was -$1.8 billion, a 2776.24% decrease from a year earlier, with the FY2025 full-year figure at $295.5 million, up 365.48% from the prior year.
  • Cash from Investing Activities for Q1 2026 stood at -$2.1 billion, down from $322.3 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for ALKS reached as high as $322.3 million in Q4 2025 and fell as low as -$2.1 billion in Q1 2026.
  • Historically, Cash from Investing Activities has averaged -$112.0 million across 5 years, with a median of -$13.9 million in 2024.
  • Across the five-year window, Cash from Investing Activities jumped 3838.54% in 2022 and sank 22919.16% in 2026, its largest moves.
  • Year by year, Cash from Investing Activities stood at $27.7 million in 2022, then slumped by 175.64% to -$21.0 million in 2023, then surged by 33.87% to -$13.9 million in 2024, then surged by 2423.21% to $322.3 million in 2025, then tumbled by 744.34% to -$2.1 billion in 2026.
  • Per Business Quant data, the three most recent Cash from Investing Activities figures were -$2.1 billion in Q1 2026, $322.3 million in Q4 2025, and -$6.7 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 229.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -87.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -369.95 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 743.70 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 277.40 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -506.20 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -60.00 Mn
10 Alkermes 9.72 Bn 9.21 Bn 331.33 Mn -2.08 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 -2.08 Bn
Mar 31, 2026 -2.08 Bn
Dec 31, 2025 322.35 Mn
Dec 31, 2025 322.35 Mn
Sep 30, 2025 -6.74 Mn
Sep 30, 2025 -6.74 Mn
Jun 30, 2025 -29.21 Mn
Jun 30, 2025 -29.21 Mn
Mar 31, 2025 9.10 Mn
Mar 31, 2025 9.10 Mn
Dec 31, 2024 -13.88 Mn
Dec 31, 2024 -13.88 Mn
Sep 30, 2024 -109.33 Mn
Sep 30, 2024 -109.33 Mn
Jun 30, 2024 51.85 Mn
Jun 30, 2024 51.85 Mn
Mar 31, 2024 -39.95 Mn
Mar 31, 2024 -39.95 Mn
Dec 31, 2023 -20.98 Mn
Dec 31, 2023 -20.98 Mn